SELLAS Life Sciences (SLS) Net Equity Issued and Repurchased (2011 - 2023)

SELLAS Life Sciences (SLS) has 13 years of Net Equity Issued and Repurchased data on file, last reported at $21000.0 in Q4 2023.

• On a quarterly basis, Net Equity Issued and Repurchased fell 97.74% year-over-year to $21000.0 in Q4 2023; TTM through Sep 2024 was $21000.0, a 98.25% decrease from a year earlier, with the FY2023 full-year figure at $289000.0, down 72.42% from the prior year.
• Net Equity Issued and Repurchased for Q4 2023 stood at $21000.0, down from $268000.0 in the prior quarter.
• Over the last five years, Net Equity Issued and Repurchased for SLS reached as high as $15.1 million in Q4 2020 and fell as low as -$129000.0 in Q3 2019.
• Historically, Net Equity Issued and Repurchased has averaged $3.8 million across 5 years, with a median of $929000.0 in 2022.
• Across the five-year window, Net Equity Issued and Repurchased sank 100.6% in 2019 and surged 6682.95% in 2020, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $2.3 million in 2019, then jumped by 553.04% to $15.1 million in 2020, then plunged by 85.21% to $2.2 million in 2021, then sank by 58.53% to $929000.0 in 2022, then slumped by 97.74% to $21000.0 in 2023.
• Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $21000.0 in Q4 2023, $268000.0 in Q1 2023, and $929000.0 in Q4 2022.